<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Spring Bank Pharmaceuticals, Inc.

    Spring Bank Pharmaceuticals, Inc.

    Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...

    Spring Bank is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    I-PASS Patient Safety Institute, Inc.

    I-PASS Patient Safety Institute, Inc.

    We help save lives by improving verbal and written communications that occur betwe...

    We help save lives by improving verbal and writ...

    Amount Raised:    $149,055.00
    Fundraising Status:    EC
    Filing Type:    CF
    Trevi Therapeutics, Inc.

    Trevi Therapeutics, Inc.

    We are developing nalbuphine ER to treat serious neurologically mediated condition...

    We are developing nalbuphine ER to treat seriou...

    Filing Type:    PU
    Daiichi Sankyo Co., Ltd.

    Daiichi Sankyo Co., Ltd.

    Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...

    Founded on September 28, 2005 through the merge...

    Filing Type:    PU
    Aptinyx Inc.

    Aptinyx Inc.

    Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...

    Aptinyx Inc. is a clinical-stage biopharmaceuti...

    Filing Type:    PU
    Eagle Pharmaceuticals, Inc.

    Eagle Pharmaceuticals, Inc.

    Eagle is a specialty pharmaceutical company working to advance safe and efficient ...

    Eagle is a specialty pharmaceutical company wor...

    Filing Type:    PU
    Cellectis S.A.

    Cellectis S.A.

    Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...

    Cellectis is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Exelixis, Inc.

    Exelixis, Inc.

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncol...

    Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) ...

    Filing Type:    PU
    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...

    Atara Biotherapeutics is a leading off-the-shel...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.